News and Trends 12 Oct 2022
Ascidian Therapeutics launches with $50M to rewrite RNA
…therapy while reducing risks associated with DNA editing and manipulation. Boston, U.S.-based Ascidian was created in 2020 with $50 million in committed series A funding from ATP to advance its…